Open Access

Nanoscale Au@SiO2‑drug/VEGF as an in vivo probe for osteosarcoma diagnosis and therapy

  • Authors:
    • Tiangui Chen
    • Tianbo Li
    • Jiangning Wang
  • View Affiliations

  • Published online on: September 8, 2021     https://doi.org/10.3892/ol.2021.13027
  • Article Number: 766
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma is a common primary bone malignancy, with a 5‑year survival rate of only 20‑30% in patients undergoing surgical treatment. Thus, it is important to identify novel methods for diagnosing and treating osteosarcoma, which was the aim of the present study. Vascular endothelial growth factor (VEGF) was used as the tumor‑targeting protein to synthesize a multifunctional core‑shell nanostructure, Au@SiO2‑drug/VEGF, in which the drug can be indocyanine green (ICG; as an optical tracer) or doxorubicin (DOX; as a chemotherapeutic agent). With VEGF as the osteosarcoma‑targeting protein, Au exhibited optimal photothermal transformation performance, while SiO2 served as the carrier for the drug. Au@SiO2‑ICG/VEGF nanoparticles (NPs) were evaluated for imaging and for the monitoring of drug accumulation in a tumor region in mice. Once the optimal drug accumulation was achieved, combined treatment of osteosarcoma (chemotherapy and photothermal therapy) was assessed. In the perioperative period associated with minimal invasive embolization of osteosarcoma, photothermal therapy and chemotherapy were applied for osteosarcoma diagnosis using Au@SiO2‑DOX/VEGF NPs. Taken together, the results of the present study provide a promising strategy for tumor detection prior to surgical treatment to improve the survival outcome of patients with osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen T, Li T and Wang J: Nanoscale Au@SiO<sub>2</sub>‑drug/VEGF as an <em>in vivo</em> probe for osteosarcoma diagnosis and therapy. Oncol Lett 22: 766, 2021
APA
Chen, T., Li, T., & Wang, J. (2021). Nanoscale Au@SiO<sub>2</sub>‑drug/VEGF as an <em>in vivo</em> probe for osteosarcoma diagnosis and therapy. Oncology Letters, 22, 766. https://doi.org/10.3892/ol.2021.13027
MLA
Chen, T., Li, T., Wang, J."Nanoscale Au@SiO<sub>2</sub>‑drug/VEGF as an <em>in vivo</em> probe for osteosarcoma diagnosis and therapy". Oncology Letters 22.5 (2021): 766.
Chicago
Chen, T., Li, T., Wang, J."Nanoscale Au@SiO<sub>2</sub>‑drug/VEGF as an <em>in vivo</em> probe for osteosarcoma diagnosis and therapy". Oncology Letters 22, no. 5 (2021): 766. https://doi.org/10.3892/ol.2021.13027